109 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
Research and development
Selling, general and administrative
Total operating costs and expenses
Loss from operations
Interest and other, net:
Interest … cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research
8-K
EX-99.1
nojnz
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
d7spkawq
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
4lt9st
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
4pwxu84thvd31ijhk
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
rwtr719
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
EX-99.1
rec0pb6pcu
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
ho4s2
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
zr7 os0tmezes4
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am